Comparative Pharmacology
Head-to-head clinical analysis: CIPRO XR versus IQUIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO XR versus IQUIX.
CIPRO XR vs IQUIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription.
DNA gyrase inhibitor; topoisomerase IV inhibitor; bactericidal against Gram-positive and Gram-negative bacteria by blocking DNA replication.
500 mg to 1000 mg orally once daily for 7 to 14 days; extended-release tablet must be swallowed whole and administered with food.
1-2 drops of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1-2 drops every 4 hours while awake for up to 5 days total.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function, allowing twice-daily dosing; due to extended-release formulation, ciprofloxacin is released over 24 hours.
Terminal elimination half-life is approximately 4-6 hours. This short half-life supports twice-daily dosing in clinical practice (for ophthalmic suspension).
Renal excretion of unchanged drug accounts for approximately 40-50% of the dose; hepatic metabolism (glucuronidation, sulfation) produces active metabolites, and biliary/fecal elimination (via feces) accounts for 20-35% of the dose.
Primarily renal excretion of unchanged drug (approximately 70-80%). A smaller fraction is excreted as metabolites via the kidneys. Biliary/fecal elimination accounts for less than 10% of the dose.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic